Factory high quality Galantamine Hydrobromide

Superiority:

galanthamine hydrobromide

CAS: 1953-04-4;69353-21-5

Molecular Formula: C17H22BrNO3

1. Home
2. Product Category
3. Drug substance
4. Nervous system medication
5. 69353-21-5

69353-21-5 - Names and Identifiers

69353-21-5 - Physico-chemical Properties

1. take about 1 mg of this product, put it in a porcelain evaporation dish, add 1ml of 0.5% ammonium molybdate solution, steam dry on a water bath, and add 1-2 drops of sulfuric acid to show blue-green color.
2. take this product and Galanthamine Hydrobromide reference, respectively, with the relevant substances under the mobile phase dissolved and diluted to make each lml containing about 0. The lmg solution is used as the test solution and the reference solution, and the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution according to the chromatographic conditions of the related substances.
3. the product of the aqueous solution of the identification of bromide reaction (General 0301).

4. Related substances

   take this product, add mobile phase to dissolve and quantitatively dilute to prepare a solution containing lmg per lml as a test solution; Take 1ml for precision measurement and put it in a 100ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the determination of high performance liquid chromatography (General rule 0512), with eighteen alkyl silane bonded silica gel as filler, with triethylamine phosphate buffer solution (take triethylamine 7ml, add water 900ml, the pH value was adjusted to 0.5 with 6.0 mol/L phosphoric acid solution, and water was added to ML)-methanol (75:25) as mobile phase, and the detection wavelength was 228nm. Take an appropriate amount of likelamine hydrobromide and dilute it with the above test solution to make about 0 ml/ml of likelamine hydrobromide. For the mixed solution of lmg and Galanthamine Hydrobromide (about lmg), take 20u1 and inject it into the liquid chromatograph. The separation degree of the peak and the main component peak should meet the requirements. 20ul of the above control solution and 20ul of the test solution were respectively injected into the human liquid chromatograph, and the chromatogram was recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (1.0% ) , the sum of each impurity peak area shall not be greater than 2 times (2.0%) of the main peak area of the control solution.